Clinical Trial Update: A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients [Phase 1]

View source ↗

Summary

Phase 1 study to assess single and multiple doses of IkT-148009 in healthy elderly participants and patients with Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IkT-148009 (IkT-148009)

Snippet

Sponsor: ABLi Therapeutics, Inc. | Conditions: Healthy Elderly, Parkinson Disease | Phase 1 | Status: COMPLETED